<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409578</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100A2347</org_study_id>
    <nct_id>NCT00409578</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multinational Clinical Trial to Evaluate the Efficacy of Aliskiren and Valsartan Versus Placebo in Lowering Levels on NT-proBNP in Stabilized Patients Post Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The TIMI Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that the inhibition of the
      renin-angiotensin-aldosterone system (RAAS) with the angiotensin receptor blocker valsartan
      or the renin antagonist aliskiren will improve ventricular hemodynamics, as reflected by a
      greater reduction in levels of N-terminal proB-type natriuretic peptide (NT-proBNP) compared
      to placebo in subjects stabilized following acute coronary syndrome (ACS) who are determined
      to be at high risk due to an elevated concentration of natriuretic peptides.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Cardiac Event</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Composite Clinical-biochemical Event</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =&gt; 200 pg/mL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1101</enrollment>
  <condition>Post Acute Coronary Syndrome</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets and capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 320 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aliskiren/valsartan 300/320 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren 300 mg</intervention_name>
    <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.</description>
    <arm_group_label>Aliskiren 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 320 mg</intervention_name>
    <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.</description>
    <arm_group_label>Valsartan 320 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren/valsartan 300/320 mg</intervention_name>
    <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.</description>
    <arm_group_label>Aliskiren/valsartan 300/320 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients 18 years old or older

          -  Subjects who are hospitalized for ischemic chest discomfort at rest lasting at least
             10 minutes and consistent with cardiac ischemia

          -  Final diagnosis of acute coronary syndrome

          -  Elevated concentrations of natriuretic peptide 3-10 days after admission for their
             qualifying acute coronary syndrome event

        Exclusion Criteria:

          -  Known or suspected contraindications, including history of allergy or hypersensitivity
             to angiotensin receptor blockers (ARBs), renin antagonists, or to drugs with similar
             chemical structures.

          -  Presence of clinically overt heart failure

          -  Known evidence of left ventricular systolic dysfunction

          -  Percutaneous coronary intervention (PCI) less than 24 hours before randomization.

          -  Patients on chronic ACEI or ARB therapy for whom therapy with an ACEI or ARB is
             clinically required with no reasonable alternative therapy available.

        Other protocol-defined inclusion/exclusion criteria applied to the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Braunwald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>TIMI Study Group, Boston, MA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Site</name>
      <address>
        <city>Investigative Site</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2006</study_first_posted>
  <results_first_submitted>January 11, 2011</results_first_submitted>
  <results_first_submitted_qc>January 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 2, 2011</results_first_posted>
  <last_update_submitted>April 15, 2011</last_update_submitted>
  <last_update_submitted_qc>April 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Post acute coronary syndrome</keyword>
  <keyword>Acute</keyword>
  <keyword>coronary syndrome</keyword>
  <keyword>B-type natriuretic peptide</keyword>
  <keyword>N-terminal</keyword>
  <keyword>pro-B-type natriuretic peptide</keyword>
  <keyword>myocardial infarctions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablets and capsules</description>
        </group>
        <group group_id="P2">
          <title>Aliskiren 300 mg</title>
          <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
        </group>
        <group group_id="P3">
          <title>Valsartan 320 mg</title>
          <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
        </group>
        <group group_id="P4">
          <title>Aliskiren/Valsartan 300/320 mg</title>
          <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="280"/>
                <participants group_id="P2" count="271"/>
                <participants group_id="P3" count="269"/>
                <participants group_id="P4" count="281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="228"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="215"/>
                <participants group_id="P4" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="67"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value(s)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablets and capsules</description>
        </group>
        <group group_id="B2">
          <title>Aliskiren 300 mg</title>
          <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
        </group>
        <group group_id="B3">
          <title>Valsartan 320 mg</title>
          <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
        </group>
        <group group_id="B4">
          <title>Aliskiren/Valsartan 300/320 mg</title>
          <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="280"/>
            <count group_id="B2" value="271"/>
            <count group_id="B3" value="269"/>
            <count group_id="B4" value="281"/>
            <count group_id="B5" value="1101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11.8"/>
                    <measurement group_id="B2" value="63" spread="11.7"/>
                    <measurement group_id="B3" value="64" spread="11.6"/>
                    <measurement group_id="B4" value="63" spread="11.1"/>
                    <measurement group_id="B5" value="63" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="197"/>
                    <measurement group_id="B4" value="194"/>
                    <measurement group_id="B5" value="753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8</title>
        <description>Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets and capsules</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 300 mg</title>
            <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren/Valsartan 300/320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in N-terminal proB-type Natriuretic Peptide (NT-proBNP) at Week 8</title>
          <description>Blood samples for the measurement of NT-proBNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.</description>
          <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="246"/>
                <count group_id="O4" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.582" lower_limit="0.502" upper_limit="0.676"/>
                    <measurement group_id="O2" value="0.563" lower_limit="0.483" upper_limit="0.656"/>
                    <measurement group_id="O3" value="0.614" lower_limit="0.526" upper_limit="0.716"/>
                    <measurement group_id="O4" value="0.635" lower_limit="0.548" upper_limit="0.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8</title>
        <description>Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets and capsules</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 300 mg</title>
            <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren/Valsartan 300/320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in B-type Natriuretic Peptide (BNP) at Week 8</title>
          <description>Blood samples for the measurement of BNP were collected, processed, and shipped to the TIMI Biomarker Core Laboratory, Boston MA for storage and analysis. The change from baseline to Week 8 was expressed as the geometric mean of the ratio: Week 8/Baseline.</description>
          <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="229"/>
                <count group_id="O3" value="237"/>
                <count group_id="O4" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.642" lower_limit="0.535" upper_limit="0.770"/>
                    <measurement group_id="O2" value="0.597" lower_limit="0.495" upper_limit="0.720"/>
                    <measurement group_id="O3" value="0.670" lower_limit="0.554" upper_limit="0.810"/>
                    <measurement group_id="O4" value="0.682" lower_limit="0.568" upper_limit="0.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Cardiac Event</title>
        <description>A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets and capsules</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 300 mg</title>
            <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren/Valsartan 300/320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Cardiac Event</title>
          <description>A cardiac event was defined as at least one of the following events: Cardiovascular death, recurrent myocardial infarction (MI), or hospitalization for congestive heart failure (CHF), all to be confirmed by adjudication.</description>
          <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="4.9"/>
                    <measurement group_id="O3" value="4.9"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Composite Clinical-biochemical Event</title>
        <description>A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =&gt; 200 pg/mL.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets and capsules</description>
          </group>
          <group group_id="O2">
            <title>Aliskiren 300 mg</title>
            <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
          </group>
          <group group_id="O4">
            <title>Aliskiren/Valsartan 300/320 mg</title>
            <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Composite Clinical-biochemical Event</title>
          <description>A composite clinical-biochemical event was defined as at least one of the following events: cardiovascular death confirmed by adjudication, recurrent MI confirmed by adjudication, hospitalization for CHF confirmed by adjudication, and/or NT-proBNP =&gt; 200 pg/mL.</description>
          <population>Full analysis set: All patients who were correctly randomized. Missing baseline values were not imputed. The last post-baseline biomarker measurement collected was used for analysis. In the aliskiren treated group, 4 patients never received study drug but were included in the full analysis set but were not included in any efficacy analyses.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="268"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="73.5"/>
                    <measurement group_id="O3" value="77.2"/>
                    <measurement group_id="O4" value="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Safety set: All patients that received at least 1 dose of study drug. Missing values were not imputed. In the aliskiren group, 4 patients were excluded because they never received study drug. One patient who never received study drug was included in the safety set because he had a date for the end of study treatment on the study completion page.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablets and capsules</description>
        </group>
        <group group_id="E2">
          <title>Aliskiren 300 mg</title>
          <description>Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
        </group>
        <group group_id="E3">
          <title>Valsartan 320 mg</title>
          <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study.</description>
        </group>
        <group group_id="E4">
          <title>Aliskiren/Valsartan 300/320 mg</title>
          <description>Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Postinfarction angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ECG signs of myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic unconsciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="279"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="278"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="264"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="268"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="279"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

